In October, Journal of Clinical Pathways (JCP) editorial board member and Discern Health Partner Tom Valuck joined colleagues from the Community Oncology Alliance and the University of Chicago for the JCP Oncology Clinical Pathways Congress panel, “The Oncology Care Model: Current Opinions and Future Perspectives.”
During the panel, participants summarized the strengths and weaknesses of the current Oncology Care Model (OCM), one of the most advanced efforts yet to shift the delivery of health care from a fee-for-service model to a fee-for-value model. The panelists also discussed the importance of gaining a better understanding of the OCM through lessons learned, from both community and academic settings, and understanding the challenges to implementation in order to inform the creation of the next version of the OCM. In addition, they theorized how the next version of the OCM may be designed and what role it will play in future health care systems.
Discern created a Congress summary, which includes an overview of key themes and a session highlight from the presentation “Biosimilars and Oncology Clinical Pathways: Perfect Together.” Download the summary here.